CSTLCastle Biosciences Inc
CSTL
Castle Biosciences Inc1,000
Mkt Cap
$738.52MVolume
63,294.0052W High
$44.2852W Low
$14.59PE Ratio
-29.32CSTL Fundamentals
Price
$25.07Prev Close
$24.84Open
$25.2450D MA
$30.55Beta
1.01Avg. Volume
360,459.61EPS (Annual)
-$0.8334P/B
1.57Rev/Employee
$389,840.32$865.07
Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at...
PR Newswire·10d ago
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk
Castle Biosciences (NASDAQ:CSTL) executives and clinical collaborators used a DecisionDx-Melanoma webcast to review results from the multicenter DECIDE study, which the company said was recently published in Future Oncology. The discussion focused on how the company's 31-gene expression profile (31...
MarketBeat·14d ago
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rati...
MarketBeat·14d ago
Castle Biosciences (NASDAQ:CSTL) Insider Sells $483,594.50 in Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 18,650 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold...
MarketBeat·17d ago
Derek Maetzold Sells 650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 650 shares of the business's stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $25.39, for a total value of $16,503.50. Following the completion of the transaction, the...
MarketBeat·18d ago
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 18,650 Shares of Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 18,650 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $25.93, for a total transaction of $483,594.50. Following the transaction, the insider directly owned...
MarketBeat·18d ago
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
Zacks·20d ago
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.
Zacks·20d ago
Castle Biosciences (NASDAQ:CSTL) Insider Sells 20,863 Shares
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Tobin Juvenal sold 20,863 shares of the firm's stock in a transaction on Thursday, March 12th. The stock was sold at an average price...
MarketBeat·20d ago
Castle Biosciences (NASDAQ:CSTL) Insider Sells $526,582.12 in Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Tobin Juvenal sold 20,863 shares of the business's stock in a transaction that occurred on Thursday, March 12th. The stock was sold at...
MarketBeat·21d ago
<
1
2
...
>